Five things to watch in markets in the week ahead
Investing.com - Evercore ISI upgraded Repligen (NASDAQ:RGEN) from In Line to Outperform on Monday, while raising its price target to $155.00 from $130.00, representing approximately 25% upside potential. The stock has shown momentum with a 7.5% gain over the past week, according to InvestingPro data.
The upgrade follows several challenging years for Repligen, which faced headwinds from COVID-related comparisons, destocking issues, and complications related to Sarepta’s AAV programs. While currently not profitable, InvestingPro analysis indicates expected profitability this year, with analysts forecasting EPS of $1.69 for 2025.
Evercore’s new price target equates to approximately 71 times 2026 price-to-earnings ratio or about 10 times 2026 enterprise value-to-sales ratio, which the firm notes is in line with Repligen’s pre-COVID valuation metrics.
The research firm indicated that while Repligen’s valuation has historically been difficult to justify, the current situation appears more favorable as the company’s outlook is "clean" with numbers "biased toward the upside."
Evercore’s long-term valuation framework for the price target equates to approximately 35 times normalized 2027 earnings per share, assuming long-term margins reach the high 20% range.
In other recent news, Repligen Corporation has entered into a strategic partnership with Novasign, an Austrian company specializing in bioprocess development. The collaboration aims to integrate Novasign’s machine learning and modeling technology into Repligen’s filtration systems, with Repligen making an investment to aid Novasign’s expansion. This partnership was also highlighted by H.C. Wainwright, which reiterated its Buy rating on Repligen, setting a price target of $180.00. Additionally, Repligen announced the appointment of Violetta Hughes as the new chief accounting officer, effective September 1, 2025. Hughes brings over 25 years of experience in the life sciences and pharmaceutical sectors.
Analysts from TD Cowen and Stifel have also maintained their Buy ratings on Repligen, with price targets of $200.00 and $207.00, respectively. TD Cowen expressed confidence in Repligen’s steady growth dynamics over the next five years. Meanwhile, Stifel’s analysis, based on customer research, emphasized the importance of Repligen’s ATF technology in bioprocessing. These developments reflect continued confidence from major investment firms in Repligen’s strategic direction and product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.